Is DexCom, Inc. (DXCM) a Buy, Sell, or Hold?
NASDAQ : DXCM
DexCom, Inc.
$83.45 USD
$8.91 (11.95%)
- Volume
- 11.98M
- Average Volume
- 5.71M
- Market Capitalization
- $31.49B
- P/E Ratio
- 32.22
- Dividend Yield
- 0.00%
- Price Target
- $91.50
- Year High
- $84.70
- Year Low
- $54.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.73
Company Overview
NASDAQ
Jacob Steven Leach
Medical - Devices
Healthcare
DXCM
11100
US
USD
Liquidity Metrics
0.51
1.73
1.43
0.47
0.00
Sales & Valuation
$4.66B
6.34
12.21
22.41
3.66
Profitability
$2.09
$836.3M
20.12%
25.76%
36.19%
15.49%
P/E Metrics
32.22
0.42
0.42
Analyst Price Target & Rating
$91.50
$105.00
$64.00
3/5
52 Analysts
-8.80%
Financial Health Scores
7.31
8/9
$1.73B
$6.46B
$3.83B
$1.3B
Key Metrics (TTM)
$31.73B
6.39
20.35
1.73
36.19%
21.60%
3.12%
4.46%
$20.01
235 days
Company Executives
| Name | Title |
|---|---|
| Christine Pospisil | Director of Medical Science & Education |
| Donald Abbey | Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs |
| Jereme Sylvain | Executive Vice President, Chief Financial Officer & Chief Accounting Officer |
| Jon Coleman | Executive Vice President & Chief Commercial Officer |
| Matthew Dolan | Executive Vice President of Strategy & Corporate Development |
| Peter Simpson | Executive Vice President & Chief Technology Officer |
| Michael Brown | Executive VP, Chief Legal & Compliance Officer |
| Sadie Stern | Executive VP, Chief People & Culture Officer |
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Sean Christensen | Vice President of Finance and Investor Relations |
| Keri Leone | Senior Director of Global Medical Science & Education |
| Jacob Steven Leach | President, CEO & Director |
Poll Results
No votes yet today — be the first to share your view!
About DexCom, Inc. (NASDAQ:DXCM) Stock
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, Dex ... Com, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise
2026-07-31 14:42:03
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
2026-07-31 00:04:00
Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Revenue: $933 million, up 11% year-over-year.International Revenu
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
2026-07-30 22:03:14
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
DexCom Q2 Earnings Call Highlights
2026-07-30 19:04:40
DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
2026-07-30 18:26:05
DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.48 per share a year ago.
Dexcom raises annual revenue forecast on strong demand for glucose monitors
2026-07-30 16:32:51
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar levels, sending shares of the company up over 4% in extended trading.
Dexcom Reports Second Quarter 2026 Financial Results
2026-07-30 16:02:00
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
2026-07-29 16:34:00
They may profit from the rapidly growing GLP-1 market in very different ways.
Frequently Asked Questions
-
What is the current DexCom, Inc. (DXCM) stock price?
-
DexCom, Inc.(NASDAQ:DXCM) stock price is $83.45 in the last trading session. During the trading session, DXCM stock reached the peak price of $84.7 while $54.11 was the lowest point it dropped to. The percentage change in DXCM stock occurred in the recent session was 11.95% while the dollar amount for the price change in DXCM stock was $8.91.
-
DXCM's industry and sector of operation?
-
The NASDAQ listed DXCM is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of DXCM?
-
Christine Pospisil | Director of Medical Science & Education
Donald Abbey | Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs
Jereme Sylvain | Executive Vice President, Chief Financial Officer & Chief Accounting Officer
Jon Coleman | Executive Vice President & Chief Commercial Officer
Matthew Dolan | Executive Vice President of Strategy & Corporate Development -
How many employees does DXCM have?
-
Number of DXCM employees currently stands at 11100. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, US.
-
Link for DXCM official website?
-
Official Website of DXCM is: https://www.dexcom.com
-
How do I contact DXCM?
-
DXCM could be contacted at phone #858 200 0200 and can also be accessed through its website. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, US.
-
How many shares of DXCM are traded daily?
-
The average number of DXCM shares traded daily for last 3 months was 5.71M.
-
What is the market cap of DXCM currently?
-
The market value of DXCM currently stands at $31.49B with its latest stock price at $83.45